CBDOilReviews.com

Category: Marijuana Movement

  • Relive Everyday Launches New CBD Gummies Made with Hemp Cannabidiol and No-THC

    Relive Everyday Launches New CBD Gummies Made with Hemp Cannabidiol and No-THC

    Pennsylvania based health company Relive Everyday has just launched and released a new CBD product. Called the Everyday Gummies, this is a non-THC product designed to help users enjoy the huge benefits of CBD in a pleasant and tasty way, and without getting high.

    Users can benefit by simply chewing them like they do regular gummies. It contains both CBD and a wide range of terpenes. It’ll also serve as an excellent alternative to CBD oils, tinctures, and vapors

    HIGHSPIRE, Pa. — Relive Everyday is rolling out THC-free Everyday Gummies in two levels. Relive Everyday’s hemp extract products are said to contain all the healing and beneficial compounds, including CBD, of the industrial hemp plant without the THC. So, users looking for an excellent THC free source of hemp products will find these CBD gummies great and beneficial.

    This is the company’s goal –to help people enjoy the benefits of CBD pleasurably and without getting high. According to Amanda Witters, Co-Owner Relive Everyday,

    “We saw a need for THC-free products. People wanted an alternative to oil-based tinctures. They wanted a product that is easy to take, tastes great, and is worry-free. Relive Everyday was created to give people the CBD products they want.”

    Her partner and co-founder, Jay Miranda further reiterated the company’s strict adherence to quality, awesome line of products and their acceptance among even people living with autism.

    “Relive Everyday has evolved into so much more. Relive Everyday is Autism Approved through its partnership with the Autism Hope Alliance. We’re thrilled to collaborate with the Autism Hope Alliance. This speaks to the high quality of our products and our commitment to helping families,”

    This commitment to quality and solving problems has seen the company get nominations for

    Innovation Award by the Hemp Industries Association (HIA). This is an award that’s given to companies the industry that is at the forefront of developing new products, technologies and advancing the industry.

    In response to this, Witters says they are driven by their customers, who cause them to aspire to more.

    “Our customers guide us at Relive every day. Thanks to positive partnerships with the Autism Hope Alliance, the nomination from HIA, and our customers, we are able to create new products like high concentration gummies and affordable CBD pain relief sprays,” said Witters.

    The gummies come in two different concentrations of CBD -10mg, and 20mg- and are available in flavors like watermelon, orange and lime.

  • Leading Edge Pharms Launches New Topical Cannavera Pain Relief Ointment with Silvidiol

    Leading Edge Pharms Launches New Topical Cannavera Pain Relief Ointment with Silvidiol

    A Nevada based biotech firm recently added a new top of the line pain relief ointment to its line of products. Known as the Cannavera Pain Relief Ointment, this is the latest offering in the company’s line of cannabis-based oils, sprays and creams.

    Leading Edge Pharms specializes in creating products with innovative delivery systems and unique cannabinoid therapies meant to help users get the relief they need almost instantly.

    This latest product contains a nano-encapsulated compound called Silvidiol Liposome. This is a truly outstanding compound –currently awaiting patent approval- made up of emerald aloe vera and liposomal hemp, and created to help provide relief to patients suffering from nerve, joint, and muscular pains, as well as skin irritations triggered by inflammation.

    In the company’s announcement of the product, David Chadwick, CEO of Leading Edge Pharms said the new product is a proven product, that doesn’t contain THC, and designed to maximally treat and provide pain relief. It does this by being rapidly absorbed in the skin, with the compound getting delivered straight to the pain receptors. According to him,

    “Our new topical pain relief ointment provides another application option for our proven THC-free pain management treatments. While many CBD-based ointments are reaching the market, our Silvidiol Liposome, which forms the basis of our Cannavera products, has been proven as an effective delivery method able to permeate the skin to reach pain receptors and alleviate aches caused by injury or inflammation,” […] “We continue to pursue our goal of providing natural, safe and effective cannabinoid therapies through innovative delivery systems, answering a real market need for opioid-alternatives for pain relief.”

    The new Cannavera Pain Relief Ointment is also accompanied by the company’s release of new smaller sized containers for its more popular sprays and cream. Users can now get them in small 30ml/1oz containers. These are great for carrying around, and applying on the go when you need frequent applications.

  • President Donald Trump’s Surgeon General “Mostly Good” on Cannabis Legalization

    President Donald Trump’s Surgeon General “Mostly Good” on Cannabis Legalization

    Jerome Adams, the current surgeon general, has recognized that there is an ongoing opiate crisis that is impacting the nation and that it is one of the foremost challenges that the country is facing. Interestingly enough, his time as the surgeon general is marked by a transition to another type of substance – medical marijuana. The big question that arises is whether drug policy reform may continue and whether it can displace the current epidemic.

    A few months ago, Adams stated to an audience in Boston that their marijuana, which is classified as highly dangerous, addictive, and that has no known medical benefits, should be reexamined. There is no research to support the assertions concerning marijuana and it may be time to move forward. However, he then clarified and stated that he does not favor legalization or rescheduling, but he is looking for “evidence-based findings.”

    January 2019 featured “National Drug and Alcohol Facts Week.” During the pertinent week, Adams tweeted about marijuana and other medical professionals had called him out on it. In this tweet, he stated,

    “No child should ever use #marijuana. It is not safe for the developing brain and it affects learning and memory.”

    He then changed the tweet to

    “No child should use #marijuana/products non medically.”

    This seems to be in-tune with the FDA’s most recent move on marijuana, which was releasing a marijuana-derived pharmaceutical drug for a very specific purpose – which is to treat a certain type of epilepsy in children.

    It will be interesting to see what happens going forward and how Adam’s stance may change and evolve with the administration. Of course, because his office is a political one, there may be limits to what can be said and done.

  • Here’s How 2020 Presidential Candidate John Delaney’s Stance on Cannabis and Hemp Looks

    Here’s How 2020 Presidential Candidate John Delaney’s Stance on Cannabis and Hemp Looks

    With the 2020 elections just a year away, cannabis users, policymakers, dispensaries, growers and manufacturers are concerned about where the various candidates stand on the cannabis or marijuana.

    One of these candidates is Former U.S. Rep. John Delaney (D-MD), who intends to run for the White House. While he’s not as popular as a few other intending candidates, his opinion still counts.

    Along with other candidates, he shares their support for the reform of federal marijuana laws. While he hasn’t vocally supported the legalization of marijuana across the country, he has shown that he’s willing to support it through multiple favorable votes in favor of marijuana law reforms and amendments on the floor of the House.

    Support Through Policy and Legislation

    While he was in Congress, the former House of Rep member proved his commitment to the “cannabis cause” in the country by co-sponsoring seven marijuana-related bills –he didn’t introduce any directly.

    One of these bills was for the removal of cannabidiol (CBD) from the Controlled Substances Act. A second bill was for the protection of individuals and entities taking part in any form of cannabis activity, from federal laws and interference, in states where cannabis is legalized.

    A third bill was one focused on the protection of patients who needed to use medical marijuana to ease their symptoms in cannabis legalized states. A fourth bill was for the protection of banks backing marijuana businesses or activities from federal prosecution or fines.

    He backed bills restricting the federal government from penalizing banks that worked with state-approved and compliant marijuana businesses.

    The congressman also voted in support of clamping down on federal marijuana enforcement. He was actively involved in the amendments of bills that would provide protection and safety to states where cannabis was legally approved for medical conditions.

    He also backed bills and laws aimed at protecting marijuana states with legal backing from the Justice Department.

    He supported an amendment allowing doctors with the U.S. Department of Veterans Affairs, prescribe medical marijuana for veterans who needed it in the years 2014-2016, as well as voted in support of several amendments aimed at lifting federal restrictions on industrial cannabis.

    Public Declaration of Support

    Even though Delaney had a reputation for backing pro-marijuana bills and amendments, he doesn’t really say much about the plant in public. Posts about cannabis are nonexistent on his social media handles, unlike many other Democrat candidates who frequently post about the plant, bills, amendments and issues.

    The few times he’s speaking directly about marijuana in public include his Washington Post statement against a withdrawn federal marijuana policy guideline by the then Attorney General, Jeff Sessions.

    The post stated, “The Cole Memo provided clear guidance to an otherwise conflicting situation,” […] “Revoking the Cole Memo will restore that confusion and undermines the will of the voters in several states.”

    Before that, in 2013, his office was stated to have issued a statement to the daily the Daily Kos quotes about his position on marijuana. It stated that

    “while federal, state, and local laws pertaining to marijuana do lead to criminal justice costs, there is also a risk that decriminalization or legalization might further exacerbate these costs.”

    In 2018, during an interview about his book on C-SPAN, former interim Democratic National Committee chair Donna Brazile, said that his book didn’t contain any details on issues like marijuana legislation or criminal justice reform.

    In response, Delaney stated that he supported a reform of the criminal justice system, but left out any mention of marijuana legalization.

    Future of Marijuana if Delaney Becomes President

    Delaney has shown consistent support of marijuana legislation, particularly that shielding the states from federal interference or fines. Therefore, it’s safe to assume that the legal marijuana industries will continue to thrive in a Delaney presidency.

    Whether this will change remains to be seen, if he becomes president. Till then, John Delaney seems like a Democrat candidate who will help improve the marijuana landscape.

  • New Marijuana Study Indicates CBD Might Increase the Psychoactive Effects of THC

    New Marijuana Study Indicates CBD Might Increase the Psychoactive Effects of THC

    You know it’s often said that CBD infused products with low THC quantities don’t get you high? Well, if a recent study about the impact of CBD on THC effects is anything to go by, that may no longer be true. It appears that CBD could actually help boost the feeling of being high.

    The new study which was published in the journal, European Archives of Psychiatry and Clinical Neuroscience, was carried out by some Australian research experts, indicates that CBD and THC do not work as independently as we once thought.

    The study involved 36 participants –some frequent users, others mild or non-users- who were exposed to various concentrations of vaporized marijuana to determine how both compounds worked in their bodies as well as the effects they had on them.

    All participants were given five different doses:

    • Placebo
    • 8mg of THC only
    • 400mg of CBD only
    • 8mg of THC and 4mg of CBD combined
    • 12mg of THC and 400mg of THC combined

    All participants then had their blood samples and pressure taken for the purpose of determining their severity of intoxication.

    The results from the study debunked the impression that CBD could help counteract the psychoactive effects of THC. If anything, the study proved otherwise. This was particularly obvious when the subjects took the 400mg of CBD alone. The researchers saw that those who vaped that concentration,

    “inferred intoxication but had no direct insight into the internal world of the participants, who felt intoxicated due to distinct feelings of depersonalization, derealization and altered internal and external perceptions.”

    This is a surprising and directly opposite to the previously held position that CBD doesn’t get people high, and will even temper the effects of THC. In fact, the researchers went ahead to note that,

    “No such findings have been reported in the literature in relation to high doses of CBD,”.

    Even more, the subjects claimed that they felt more intoxicated when they took the low volume CBD and THC, than when they took the THC alone. This means that small amounts of CBD just might play a role in enhancing THC’s effects. While these reports were provided by the participants themselves, independent testing of their blood plasma showed high THC levels, particularly in those who don’t smoke frequently.

    According to them,

    “While precise mechanisms remain to be elucidated, the finding that low doses of CBD may potentiate effects of THC has significant implications for consideration of proportions of THC and CBD that may be recommended within plant matter. With cannabis increasingly being used for medicinal purposes, it is important to ensure that harms are minimized in favor of boosting therapeutic properties. While intoxication per se is not necessarily harmful overall, it is not welcome by many clinical patients, and it may be harmful in situations such as driving under the influence of cannabis.”

    The concluding part of the study went on to state that CBD when in high doses, can actually counter the effects of THC. This is in accordance with past studies and research that have stated this. They wrote,

    “These findings, while specific to vaporization and requiring replication, may have implications for recommended proportions of THC and CBD in cannabis being used medicinally or recreationally within the community,”

  • Coffee Shops and Bars Add CBD (Cannabidiol) Related Beverages to Menus

    Coffee Shops and Bars Add CBD (Cannabidiol) Related Beverages to Menus

    Cannabidiol (CBD) has become a popular go-to option for men and women who are looking to experience the substance’s potential therapeutic benefits. Bars and coffee shops have taken note of all of the CBD-related products on the market and have decided to capitalize on the trend by adding CBD-related beverages to their menus.

    One such example is Eric Cahan and his business partners, who have opened a café filled with art in Manhattan’s East Village in 2018. After opening, the café added a CBD beverage to its menu and people started clamoring to try it. After taking the time to learn more about CBD, Cahan and his partners reformulated their menu to add other products to sell, such as curated oils and beverages. Now, the café makes most of its sales from CBD products and beverages and it is also working to develop a line of “functional elixirs” that are targeted at various health issues, such as reducing inflammation, focus, and sleep.

    At this point, many may be asking themselves how CBD can be sold like it is. The answer is the 2018 Farm Bill signed by President Trump in December. Although the Bill restricts companies from adding CBD to beverages, dietary supplements, and food, interestingly enough – many are doing so anyway. The FDA also intends to enforce the restriction, but while it works on creating a method for products to enter the market legally.

    Those who have tried CBD formulas seem to find it able to alleviate anxiety, sleep issues, and pain. Better yet, the stoner stereotype associated with cannabidiol is no longer the prevailing image. Rather, CBD has entered the market and became a trendy, attractive, and potentially useful for users’ day to day. On the other hand, despite the benefits that many swear by, there is no conclusive evidence showing that CBD’s effectiveness and due to the lack of regulation, the quality of CBD can vary greatly. According to Professor Ryan Vandrey at John Hopkins,

    “There’s a lot of interest and excitement, for good reason, but I think people are pushing it too hard, too fast and are overgeneralizing things.”

    Concerning clinical evidence, there is very little. Researchers are still unsure of how CBD interacts in the mind and body, but they surmise that it does have an impact on helping individuals with epilepsy, anxiety, and sleep issues. Safety is another component that may be an issue – researchers are still determining whether it is a safe solution and it is one that is still difficult to make because it is still banned under federal law. Thus, researchers who are interested in studying and learning about CBD must deal with the hurdles.

    What is known, though, is that it may be an effective solution to treating seizures experienced by children who have Lennox-Gastraut syndrome or Dravet syndrome. Research studies have been conducted by GW Pharma and the FDA approved the company’s science and ultimately, Epidiolex.

    Despite the challenges concerning safety, effectiveness, and quality, consumers are still researching for the CBD. According to Mackie,

    “It’s always nice to have strong proof in placebo-controlled trials, but if someone’s taking a drug and feeling any benefit, more power to them.”

  • Carol Bartz Former Yahoo CEO Compares CBD (Cannabidiol) to Technology Sector of 20 Years Ago

    Carol Bartz Former Yahoo CEO Compares CBD (Cannabidiol) to Technology Sector of 20 Years Ago

    Former Yahoo CEO Carol Bartz reported to CNBC’s “Squawk Alley” that she views CBD like tech 20 years ago. She also disclosed that she had invested in California-based CBD company Caliva.

    Bartz is not the only one whose invested. Joe Montana, NFL Hall of Fame, has also invested over $75 million into the company’s first fundraising round. The company manages various components of the CBD formulation process from “seed to sale” and it even grows marijuana, it creates vape oils, and it also sells its formulas at a dispensary in San Jose.

    Barz also plans to join the Caliva board. She’s stated,

    “When I saw this opportunity, I said this is the new world here. It’s like being back in tech 20 years ago. It’s like so much growth potential, so many ways to change people’s lives so I’m in.”

    One of the main growth opportunities associated with CBD is that it is non-psychoactive when it is free from THC. According to Bertz, CBD is “a very, very important part” of the CBD industry, but combination of THC and CBD may be more beneficial.

  • CBS Rejects Medical Marijuana Advertisement From Super Bowl Commercials

    CBS Rejects Medical Marijuana Advertisement From Super Bowl Commercials

    The Super Bowl is one of the biggest opportunities every year for companies to post their advertisements, considering the millions of people that watch the event every year. There are plenty of people who admittedly watch for the commercials, but one for medical marijuana has already been pulled from the lineup, according to TMZ.

    Since viewers will not be able to see it with the broadcast, TMZ posted the Acreage Holdings-produced commercial. Though the marijuana and cannabis investment firm hoped to secure their spot with CBS for $5 million, TMZ reports that it was turned down for their policy of not running marijuana advertisements on their station.

    There are three individuals featured in the advertisement – a boy with hundreds of seizures daily, an opioid addict, and a veteran amputee that suffers from tremendous pain. The advertisement gives the sufferers an opportunity to tell their stories, expressing how the use of medical marijuana is safe and how the lack of allowing this time of medication to be used is “unfair,” cruel,” and “an injustice. The three people all say, during the commercial, that the use of marijuana improves their lives.

    Clearly, the intention of Acreage Holdings is to position themselves of the size of pro-legalization of medical marijuana beyond state level, urging the nation’s government to impose new laws. Even though there are many states that are gravitating towards at least the medical use of marijuana, the approval from the federal government would break down major walls.

    The commercial concludes with a simple statement – “The time is now.” The final image that viewers would have watched urges them to speak with their local US representative or their US senator “to advocate for change now.”

    Consumers can visit the creator’s website at AcreageHoldings.com.

  • Studies Reveal Annual Direct-Selling MLM CBD Companies Sales Were Over $300 Million Worth In 2018

    Studies Reveal Annual Direct-Selling MLM CBD Companies Sales Were Over $300 Million Worth In 2018

    “Interest in cannabidiol, or CBD, is rapidly transforming the consumer product landscape,” according to Todd Eliason. The Direct Selling News (DSN) editor-in-chief could not be more right, considering that he is the one that researched the topic himself. After a prediction in October that these types of companies would be responsible for $300 million in CBD-related product sales was confirmed as true by PRNewswire this month, it is clear that there needs to be more attention on them as the years go by.

    With this level of sales, direct-selling companies are the “largest channel of distribution” for this industry, according to Direct Selling News. Eliason elaborates that the trends that the market is seeing now could easily surpass their $1 billion expected target by next year on a global scale, though PRNewswire reports that the market could even pass $39 billion by 2023. It could even pass $95 billion three years after that. This significant level of growth is encouraging for startups that are only just now getting into the cannabis industry.

    Though the Cannabis sativa plant has hundreds of cannabinoids, CBD is one of the more well-known compounds. As more research takes place, the list of health and therapeutic benefits gets longer and longer, and the industries interested in integrating it into their own brands, like dietary supplements and even pet products, are increasing in volume as well.

    As of October 2018, Direct Selling News had been able to identify a minimum of 25 direct selling companies that are already involved with CBD. The direct selling companies, sometimes called network marketing companies, use independent sales associates to sell products to customers on a one-on-one basis, rather than going through a more traditional option for independent shopping. Some of the companies that DSN specifically lists are Kannaway, a sector of Medical Marijuana, Inc., and Youngevity International, which is one of the top 100 largest direct selling companies.

    Eliason explains the interest, saying,

    “With an ingredient that is as easily misunderstood as CBD, the direct selling channel may prove to be the perfect fir for companies seeking channels of distribution. Direct sellers and network marketers are known for their one-on-one training and education methods that can meet the consumer on a personal level even if it’s the first time they’ve heard of CBD oil. That personal connection and ability to address specific misconceptions has the potential to create a loyal customer base.”

    Direct Selling News recently co-hosted the CBD Symposium in November with SUCCESS Partners, its parent company.

  • What Retail Producers Of CBD Isolates And Hemp Extracts Need To Know About Hemp CBD Products

    What Retail Producers Of CBD Isolates And Hemp Extracts Need To Know About Hemp CBD Products

    The Farm Bill of 2018 has introduced many new opportunities for consumers and retailers alike, but there are still a lot of questions. Retailers now have to pay more attention than ever to the regulations that govern them. It is clear that CBD isolates will still have to wait until the FDA establishes regulatory measures that can govern them, but there are multiple other issues to address.

    At the simplest breakdown of the Farm bill, retailers are able to sell hemp without being subjected to the Controlled Substances Act, assuming that the total THC level is under 0.3% of the product. Hemp extracts allow consumers the opportunity to explore CBD without the worry of breaking the law. Unfortunately, the word that everyone seems hooked on is cannabidiol (CBD), according to Angela Spivey, a partner at the Alston & Bird law firm.

    Spivey commented, “I’m hearing from everybody that marketing CBD on the front of the label is critical for driving sales.” However, putting CBD on the label either means that the label is incorrect, or the retailer is illegally selling the substance.

    To clarify, Perkins Cole partner Larry Reichman said, “If you are using a broad-spectrum hemp extract, but on the front, you say, ‘CBD infused,” that’s potentially misleading.” Furthermore, Reichman points out that simply writing a measurement like “25mg” on a label is misleading as well, as it does not indicate if the product contains hemp, hemp extract, or CBD.

    The FDA Needs To Step In

    Reichman believes the easiest course of action could be determined if the FDA decided to develop simple regulations about broad spectrum hemp extracts. Unfortunately, there has been no comment from the FDA at all, so the idea that they would label anything at this point is a secondary concern.

    Continuing, Reichman said,

    “[The FDA] has been quite clear about CBD and THC, but it has not talked specifically about hemp-derived extracts, so any additional guidance it can give on this would be helpful to companies seeking FDA compliance. It is clear that isolated CBD is not legal, but you start to get into a grey area with hemp extracts. What is being extracted? Has it been refined to dial up the CBD?”

    Now, the concern turns to the future for isolated CBD, considering that the FDA has no regulations now, but is “taking new steps to evaluate” if there will be regulations at all.

    Reichman expressed his prediction of what the future holds, saying,

    “The FDA could expressly permit the addition of CBD to food products by a rule, or it could produce a written policy position saying we don’t intend to enforce the prohibition [on CBD in foods/supplements]. It could also announce conditions of use under which it would not enforce [its previous position]. But you’d still have to show it is safe via a GRAS determination or a food additive petition.”

    The concern, he says, should be more about the attorneys of the plaintiff, instead of the FDA’s stance, because they will “absolutely” show up. As brands decide to comment, they should stick with the “less is more” stance when offering their remedies, because every claim must be backed up with clinical research. Presently, there is not any.

    Hemp Standards

    Spivey discussed the way that hemp extracts should be handled within food products, saying that retailers should not concern themselves with what the labels should say as much as they should concern themselves with texting and sourcing. Products from international sources are getting stuck with customs, and the local creation of these remedies allow for a higher-quality remedy.

    As far as the manufacturing of these products goes, third-party sellers should make sure they are working with companies that have their manufacturing processes in order and in accordance with industry standards.

    Elaborating, Spivey said,

    “Until now, large manufacturers that are FDA registered and compliant have not gone into the industry because it’s been such a questionable area, so you’ve got smaller companies that have been doing it without the right controls and processes. So, supply chain management will be critical in this area. Lab tests are finding contaminants across the board.”

    When offering products to consumers, retailers will need to prove their products with reliable lab testing, showing that their products are exactly what they say they are. Before now, FDA accredited labs were not doing the testing, so there were unaccredited labs performing the work. However, Spivey advises retailers to check for the CBD and THC content through an accredited lab now, appealing to the FDA.

    Azuca’s Technology For Testing

    Jonathan Teeters, a general manager for Azuca, spoke at the Winter Fancy Food Show about the interest that they have received from firms that were interested in adding isolated CBD and hemp extracts to many food products. Though there are many suppliers that are trying to get to the top of the pile, there are manufacturers that are becoming smarter about what they take on.

    Teeters said,

    “I’ve had people send two certificates of analysis [for two different products] with exactly the same readings on everything except with a different logo on the top of the page, which immediately raises red flags. You should know the farmers, know the manufacturers, know the laboratories you’re dealing with.”